136 related articles for article (PubMed ID: 30073466)
1. Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor.
Harding JJ; Bauer TM; Tan DSW; Bedard PL; Rodon J; Doi T; Schnell C; Iyer V; Baffert F; Radhakrishnan R; Fabre C; Juric D
Invest New Drugs; 2019 Apr; 37(2):271-281. PubMed ID: 30073466
[TBL] [Abstract][Full Text] [Related]
2. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies.
Munster P; Aggarwal R; Hong D; Schellens JH; van der Noll R; Specht J; Witteveen PO; Werner TL; Dees EC; Bergsland E; Agarwal N; Kleha JF; Durante M; Adams L; Smith DA; Lampkin TA; Morris SR; Kurzrock R
Clin Cancer Res; 2016 Apr; 22(8):1932-9. PubMed ID: 26603258
[TBL] [Abstract][Full Text] [Related]
3. A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.
Leong S; Moss RA; Bowles DW; Ware JA; Zhou J; Spoerke JM; Lackner MR; Shankar G; Schutzman JL; van der Noll R; Voest EE; Schellens JHM
Oncologist; 2017 Dec; 22(12):1491-1499. PubMed ID: 28798270
[TBL] [Abstract][Full Text] [Related]
4. Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.
Juric D; Krop I; Ramanathan RK; Wilson TR; Ware JA; Sanabria Bohorquez SM; Savage HM; Sampath D; Salphati L; Lin RS; Jin H; Parmar H; Hsu JY; Von Hoff DD; Baselga J
Cancer Discov; 2017 Jul; 7(7):704-715. PubMed ID: 28331003
[TBL] [Abstract][Full Text] [Related]
5. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
Bendell JC; Rodon J; Burris HA; de Jonge M; Verweij J; Birle D; Demanse D; De Buck SS; Ru QC; Peters M; Goldbrunner M; Baselga J
J Clin Oncol; 2012 Jan; 30(3):282-90. PubMed ID: 22162589
[TBL] [Abstract][Full Text] [Related]
6. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
Wicki A; Brown N; Xyrafas A; Bize V; Hawle H; Berardi S; Cmiljanović N; Cmiljanović V; Stumm M; Dimitrijević S; Herrmann R; Prêtre V; Ritschard R; Tzankov A; Hess V; Childs A; Hierro C; Rodon J; Hess D; Joerger M; von Moos R; Sessa C; Kristeleit R
Eur J Cancer; 2018 Jun; 96():6-16. PubMed ID: 29660598
[TBL] [Abstract][Full Text] [Related]
7. First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer.
Blagden S; Omlin A; Josephs D; Stavraka C; Zivi A; Pinato DJ; Anthoney A; Decordova S; Swales K; Riisnaes R; Pope L; Noguchi K; Shiokawa R; Inatani M; Prince J; Jones K; Twelves C; Spicer J; Banerji U
Clin Cancer Res; 2014 Dec; 20(23):5908-17. PubMed ID: 25231405
[TBL] [Abstract][Full Text] [Related]
8. Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
Rodon J; Braña I; Siu LL; De Jonge MJ; Homji N; Mills D; Di Tomaso E; Sarr C; Trandafir L; Massacesi C; Eskens F; Bendell JC
Invest New Drugs; 2014 Aug; 32(4):670-81. PubMed ID: 24652201
[TBL] [Abstract][Full Text] [Related]
9. A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors.
Grilley-Olson JE; Bedard PL; Fasolo A; Cornfeld M; Cartee L; Razak AR; Stayner LA; Wu Y; Greenwood R; Singh R; Lee CB; Bendell J; Burris HA; Del Conte G; Sessa C; Infante JR
Invest New Drugs; 2016 Dec; 34(6):740-749. PubMed ID: 27450049
[TBL] [Abstract][Full Text] [Related]
10. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.
Sarker D; Ang JE; Baird R; Kristeleit R; Shah K; Moreno V; Clarke PA; Raynaud FI; Levy G; Ware JA; Mazina K; Lin R; Wu J; Fredrickson J; Spoerke JM; Lackner MR; Yan Y; Friedman LS; Kaye SB; Derynck MK; Workman P; de Bono JS
Clin Cancer Res; 2015 Jan; 21(1):77-86. PubMed ID: 25370471
[TBL] [Abstract][Full Text] [Related]
11. A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors.
Carducci M; Shaheen M; Markman B; Hurvitz S; Mahadevan D; Kotasek D; Goodman OB; Rasmussen E; Chow V; Juan G; Friberg GR; Gamelin E; Vogl FD; Desai J
Invest New Drugs; 2018 Dec; 36(6):1060-1071. PubMed ID: 29980894
[TBL] [Abstract][Full Text] [Related]
12. Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors.
Wheler J; Mutch D; Lager J; Castell C; Liu L; Jiang J; Traynor AM
Oncologist; 2017 Apr; 22(4):377-e37. PubMed ID: 28275119
[TBL] [Abstract][Full Text] [Related]
13. Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.
Weiss GJ; Jameson G; Von Hoff DD; Valsasina B; Davite C; Di Giulio C; Fiorentini F; Alzani R; Carpinelli P; Di Sanzo A; Galvani A; Isacchi A; Ramanathan RK
Invest New Drugs; 2018 Feb; 36(1):85-95. PubMed ID: 28726132
[TBL] [Abstract][Full Text] [Related]
14. First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors.
Bédard PL; Davies MA; Kopetz S; Juric D; Shapiro GI; Luke JJ; Spreafico A; Wu B; Castell C; Gomez C; Cartot-Cotton S; Mazuir F; Dubar M; Micallef S; Demers B; Flaherty KT
Cancer; 2018 Jan; 124(2):315-324. PubMed ID: 28976556
[TBL] [Abstract][Full Text] [Related]
15. A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.
Rosen LS; LoRusso P; Ma WW; Goldman JW; Weise A; Colevas AD; Adjei A; Yazji S; Shen A; Johnston S; Hsieh HJ; Chan IT; Sikic BI
Invest New Drugs; 2016 Oct; 34(5):604-13. PubMed ID: 27424159
[TBL] [Abstract][Full Text] [Related]
16. Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.
Moschos SJ; Sullivan RJ; Hwu WJ; Ramanathan RK; Adjei AA; Fong PC; Shapira-Frommer R; Tawbi HA; Rubino J; Rush TS; Zhang D; Miselis NR; Samatar AA; Chun P; Rubin EH; Schiller J; Long BJ; Dayananth P; Carr D; Kirschmeier P; Bishop WR; Deng Y; Cooper A; Shipps GW; Moreno BH; Robert L; Ribas A; Flaherty KT
JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467321
[TBL] [Abstract][Full Text] [Related]
17. Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.
Edelman G; Rodon J; Lager J; Castell C; Jiang J; Van Allen EM; Wagle N; Lindeman NI; Sholl LM; Shapiro GI
Oncologist; 2018 Apr; 23(4):401-e38. PubMed ID: 29593099
[TBL] [Abstract][Full Text] [Related]
18. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
Martinez-Garcia M; Banerji U; Albanell J; Bahleda R; Dolly S; Kraeber-Bodéré F; Rojo F; Routier E; Guarin E; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Soria JC
Clin Cancer Res; 2012 Sep; 18(17):4806-19. PubMed ID: 22761467
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.
Britten CD; Adjei AA; Millham R; Houk BE; Borzillo G; Pierce K; Wainberg ZA; LoRusso PM
Invest New Drugs; 2014 Jun; 32(3):510-7. PubMed ID: 24395457
[TBL] [Abstract][Full Text] [Related]
20. A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors.
Bendell JC; Kurkjian C; Infante JR; Bauer TM; Burris HA; Greco FA; Shih KC; Thompson DS; Lane CM; Finney LH; Jones SF
Invest New Drugs; 2015 Apr; 33(2):463-71. PubMed ID: 25707361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
